Annovis Bio, Inc. (ANVS) has a negative trailing P/E of -1.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 1.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -66.83%, forward earnings yield 96.15%.
Criteria proven by this page:
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -61.8 | 0.00 | -6.05 | 0.00 | - |
| 2018 | -59.1 | 0.00 | -5.56 | 0.00 | - |
| 2019 | -66.2 | -10.60 | -7.65 | 0.00 | - |
| 2020 | -8.7 | -0.02 | 6.31 | 0.00 | - |
| 2021 | -9.3 | -0.08 | 3.01 | 0.00 | - |
| 2022 | -4.3 | -0.07 | 3.87 | 0.00 | - |
| 2023 | -3.0 | -0.03 | -21.77 | 0.00 | - |
| 2024 | -2.5 | 0.00 | 6.58 | 0.00 | - |
| 2025 | -2.5 | 0.02 | 4.22 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.16 | $0.00 | $-682K | - |
| 2018 | $-0.16 | $0.00 | $-714K | - |
| 2019 | $-0.17 | $0.00 | $-991K | - |
| 2020 | $-0.87 | $0.00 | $-5.46M | - |
| 2021 | $-1.90 | $0.00 | $-14.49M | - |
| 2022 | $-3.10 | $0.00 | $-25.33M | - |
| 2023 | $-6.23 | $0.00 | $-56.2M | - |
| 2024 | $-2,009.77 | $0.00 | $-24.59B | - |
| 2025 | $-1.40 | $0.00 | $-28.85M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.25 | $-1.25 – $-1.25 | $10.95M | $10.95M – $10.95M | 1 |
| 2027 | $-1.18 | $-1.18 – $-1.18 | $16.69M | $16.69M – $16.69M | 1 |
| 2028 | $-1.61 | $-2.01 – $-1.21 | $50.53M | $50.53M – $50.53M | 2 |
| 2029 | $-0.40 | $-0.40 – $-0.40 | $208.74M | $208.74M – $208.74M | 1 |
| 2030 | $1.70 | $1.70 – $1.70 | $385M | $385M – $385M | 1 |
